Navigation Links
Access Pharmaceuticals Reports Significant Third Party Payer Reimbursement Progress for MuGard
Date:12/9/2010

DALLAS and NEW YORK, Dec. 9, 2010 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has made significant progress in obtaining MuGard reimbursements from various third-party payer networks.  Some of the national insurance reimbursements included several state plans from Blue Cross Blue Shield, Health Net, Caremark, Well Point Next Rx, Harvard Pilgrim and Medicaid.

"Receiving these reimbursements affirms that national payers understand the critical role MuGard plays in the management of oral mucositis and serves as strong validation of the clinical and pharmacoeconomic viability MuGard offers," said Jeff Davis, President and CEO, Access Pharmaceuticals. He continued, "Our effort to land additional reimbursements is ongoing as it provides an incentive for clinics and hospitals to more quickly integrate the MuGard into their treatment protocols for cancer patients."

About Access:Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac™, a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and Thiarabine™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Ph
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
2. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
3. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
4. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
5. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
6. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
7. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
8. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
9. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
10. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
11. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014  Hologic, Inc. (NASDAQ: HOLX ) ... ended June 28, 2014. Third Quarter Financial ... to $632.6 million, reflecting operational growth of 0.5% and ... same period in the prior year. , Revenues ... Breast Health revenues grew 3.5%. , GYN Surgical ...
(Date:7/30/2014)... CUPERTINO, Calif. , July 30, 2014 ... ) second quarter 2014 financial results press release, you ... will be broadcast live over the internet on Thursday, ... pm Pacific Time). A live audio webcast ... homepage at http://www.durect.com and clicking "Investor Relations."  ...
(Date:7/30/2014)... PuraMed BioScience ® , Inc., (OTCPink:PMBS), ... medicinal and healthcare products, announced today that the ... with the name,s red and yellow logo. The ... MigraPure ®  going forward. The new name, ... migraine pain reliever will be reintroduced into selected ...
Breaking Medicine Technology:Hologic Announces Third Quarter Fiscal 2014 Operating Results 2Hologic Announces Third Quarter Fiscal 2014 Operating Results 3Hologic Announces Third Quarter Fiscal 2014 Operating Results 4Hologic Announces Third Quarter Fiscal 2014 Operating Results 5Hologic Announces Third Quarter Fiscal 2014 Operating Results 6Hologic Announces Third Quarter Fiscal 2014 Operating Results 7Hologic Announces Third Quarter Fiscal 2014 Operating Results 8Hologic Announces Third Quarter Fiscal 2014 Operating Results 9Hologic Announces Third Quarter Fiscal 2014 Operating Results 10Hologic Announces Third Quarter Fiscal 2014 Operating Results 11Hologic Announces Third Quarter Fiscal 2014 Operating Results 12Hologic Announces Third Quarter Fiscal 2014 Operating Results 13Hologic Announces Third Quarter Fiscal 2014 Operating Results 14Hologic Announces Third Quarter Fiscal 2014 Operating Results 15Hologic Announces Third Quarter Fiscal 2014 Operating Results 16Hologic Announces Third Quarter Fiscal 2014 Operating Results 17DURECT Corporation Invites You to Join its Second Quarter 2014 Earnings Conference Call 2PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 2PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 3
... Jan. 11, 2010 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ... the Company to address the dual epidemics of diabetes and ... the year and place the Company on the path to ... presented by Daniel M. Bradbury, president and chief executive officer, ...
... 11 Spherix Inc. (Nasdaq: SPEX ), an innovator ... and regulatory consulting services to food, supplement, biotechnology and pharmaceutical ... be presenting at the Annual OneMedPlace Finance Forum, which is ... Francisco, CA. Dr. Lodder will deliver the Company,s corporate ...
Cached Medicine Technology:Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference 2Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference 3Spherix to Present at Annual OneMedPlace Finance Forum and at EBD Biotech Showcase in San Francisco 2Spherix to Present at Annual OneMedPlace Finance Forum and at EBD Biotech Showcase in San Francisco 3
(Date:7/30/2014)... Steven Reinberg HealthDay ... Each year in the United States, at least 2,000 Americans ... officials said Wednesday. Heat waves, heat stroke or sun ... reported between 2006 and 2010, according to the U.S. Centers ... -- a severe loss of body heat -- accounted for ...
(Date:7/30/2014)... 2014 Volunteers from the Church of ... abuse this summer with massive distribution of Truth ... find these volunteers on Strøget, the famous Copenhagen walking ... its shopping and its ambiance, some quarter of a ... summer day. , These activities are part of ...
(Date:7/30/2014)... The family of a Vermont man ... Xarelto lawsuit ( http://www.xareltolawsuitcenter.com/ ) alleging his death ... reports. According to the complaint, which was filed in ... July 25th, the decedent had been taking Xarelto for ... bleed that ultimately led to his death on August ...
(Date:7/30/2014)... Hamilton Facial Plastic Surgery ... Carmel office on July 30th. After months of planning, ... to the state-of-the-art suite, located only steps away from ... allow for one-on-one patient comfort, shorter wait times, and ... Dr. Hamilton’s new office-suite will continue to provide the ...
(Date:7/30/2014)... DRE Medical — a leading medical ... of its Medical Trade Shows & Conventions Calendar ... and equipment vendors. , The calendar is a continually-updating ... United States and around the world. Hundreds of entries ... is always growing. , Information listed on each trade ...
Breaking Medicine News(10 mins):Health News: Extreme Weather Kills 2,000 in U.S. Each Year: CDC 2Health News: Extreme Weather Kills 2,000 in U.S. Each Year: CDC 3Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2Health News:DRE Launches Online Interactive Medical Trade Show Calendar 2
... safe and may produce beneficial changes in the brains ... to an article posted online today that will appear ... Neurology, one of the JAMA/Archives journals. , In patients ... myelin sheaths that protect nerve cells in the brain ...
... pressure may be associated with a decreasing peripheral field ... eye pressure remains low overall, according to a report ... of the JAMA/Archives journals. , Prevention of further visual ... authors write as background information in the article. Previous ...
... 13, 2007, Paying out certain types of government aid in ... harmful and often fatal drug binges, according to a new ... Economics that links the monthly arrival of disability checks with ... findings by researchers at the University of California, Santa Cruz ...
... disaster strikes, causing structural damage to DNA, players in ... contain the wreckage, scientists at The University of Texas ... edition of Cell. , This connection between a signaling ... known as chromatin remodeling "opens an entirely new category ...
... New research from scientists at UT Southwestern Medical ... the importance of preventing recurring acid reflux while also ... turn potentially cancerous. , In research published in July ... disease, particularly those with a complication of acid reflux ...
... 2007) Surgeons may have a new patient ... some of the concerns associated with the current ... August issue of the Journal of the American ... (rhThrombin) reduces the risk of surgical complications associated ...
Cached Medicine News:Health News:DNA vaccine against multiple sclerosis appears safe, potentially beneficial 2Health News:Fluctuating eye pressure associated with visual field deterioration in glaucoma patients 2Health News:Disability payments may spur drug abuse 2Health News:Chromatin remodeling complex connected to DNA damage control 2Health News:Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer 2Health News:Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer 3Health News:New study shows promise in reducing surgical risks associated with surgical bleeding 2
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Medicine Products: